Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04367883|
Recruitment Status : Recruiting
First Posted : April 29, 2020
Last Update Posted : February 2, 2021
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.
The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving treatment show a better evolution.
|Condition or disease||Intervention/treatment|
|COVID19 Influenza Vaccination ACE Inhibitors ARB||Drug: ACE inhibitor Drug: ARB|
The number of patients admitted at the hospital, their comorbidity (Charlson index), the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors) would be studied.
If patients that previously received the influenza vaccine or treated with ACEI or ARB showed a better evolution, it would be proposed to extend vaccination and the inclusion of ACE inhibidors and ARB in the treatment of infection.
|Study Type :||Observational|
|Estimated Enrollment :||2574 participants|
|Official Title:||Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-Covid19 Infection|
|Actual Study Start Date :||March 1, 2020|
|Estimated Primary Completion Date :||September 30, 2022|
|Estimated Study Completion Date :||August 31, 2023|
CST Hospital Incomes
Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020.
No intervention is performed.
Drug: ACE inhibitor
If evolution is favorable in patients treated with ACE as assessed at the first step of the study, this treatment would be added in a random selection of new admitted patients suffering Covid19, and results would be compared to a control group of admitted patients.
Other Name: ACE inhibitors to treat COVID19 infection
If evolution is favorable in patients treated with ARB as assessed at the first step of the study, this treatment would be added in a random selection of new admitted patients suffering Covid19, and results would be compared to a control group of admitted patients.
Other Name: ARB to treat COVID10 infection.
- hospital output [ Time Frame: from March 1, 2020. ]exitus vs hospital output
- hospital stay [ Time Frame: From March 1, 2020. ]lenght of the hospital stay
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04367883
|Contact: Anna Puigdellívol-Sánchez, Ph.D.||firstname.lastname@example.org|
|Contact: Mar Muñoz||34-93-7003657 ext 1895||Reserca@cst.cat|
|Hospital de Terrassa||Recruiting|
|Terrassa, Barcelona, Spain, 08227|
|Contact: Anna Puigdellívol-Sánchez, Ph.D. 34-93-5884555 email@example.com|
|Principal Investigator:||Anna Puigdellívol-Sánchez, Ph D||Consorci Sanitari de Terrassa|